iOrganBio

The Right Cells. Consistently. At Scale.

[iOrganBio @iOrganBio]

🚧 The status quo of biological model discovery, development, and biomanufacturing is blocking progress on some of humanity’s greatest biomedical breakthroughs.

At iOrganBio, we’re re-designing cell model discovery and manufacturing from the ground up, leveraging modern automation and machine learning as fundamental components of our system. Using rapid turnaround scRNA-seq, we are able to digitize cell state and automatically guide stem cell differentiation towards bioequivalency using in vivo cell states as a blueprint.

Our platform unlocks the next stage of biotechnological development, treating cells as the complex and dynamic systems that we’ve always known them to be. Join us as we transform the way we use cells to cure disease and forge progress using The Right Cells, Consistently, At Scale.

🌐 Learn more about our tech at https://t.co/GkpfmszecN
✉️ To start a collaboration with iOB, email [email protected]

[iOrganBio @iOrganBio]

iOrganBio is excited to share the addition of Zhiping Pang to our Scientific Advisory Board. As one of the world’s foremost experts in human neuron biology, synaptic function, and the molecular mechanisms underlying neuropsychiatric and metabolic disorders, Dr. Pang has co-authored over 140 publications in top journals.

As @iOrganBio continues to build our technology platform, we’re grateful to have expertise and guidance from the world’s foremost scientists, engineers, and industry leaders. Together, we’re proud to be re-shaping how cell-based research and therapies are developed, expanding access to life changing therapeutics.

🚀 Welcome aboard Zhiping!

📰 Read the full press release at https://t.co/6BL9jvKhVi
🌐 Learn more about iOB’s technology at https://t.co/FCJZoMdidY

#Neuroscience #Organoids #NAMs #DrugDiscovery #DrugDevelopment

[iOrganBio @iOrganBio]

⚡ In a rapidly changing landscape of biological modeling, agility and evidence-based decision-making are essential for new regulatory frameworks.

Earlier this month, the @ISSCR Consortium on Advanced Stem Cell-Based Models in Drug Discovery and Development—with contributions from iOB Co-Founder and Senior Scientific Advisor @ChenShuibing—provided commentary for the @FDA guidance document on NAMs for drug discovery and development. Key highlights included:

🧬 Flexibility in biological complexity and model design

🧩 Fit-for-purpose evaluation beyond comparison to traditional models

⚖️ Clarity of NAM roles within a weight-of-evidence (WoE) framework

🤖 Broader recognition of computational models and AI-integrated NAMs

📐  Right-sizing technical characterization expectations

🔎 Recognizing the unique characteristics of stem cell-derived NAMs

iOrganBio applauds ISSCR for this helpful contribution to the regulatory framework. Each of these points intersect with the challenges we are solving; from customized organoid models that allow investigation of previously unavailable biology, to scalability of consistent and reproducible cell manufacturing, to novel insights now possible through the combination of deep transcriptomics and machine learning.

🗞️ Read the ISSCR release at https://t.co/XQIZwNit1A
🌐 Learn more about the iOB tech platform at https://t.co/FCJZoMdidY
✉️ Reach out to us for partnering opportunities at [email protected]

#NAMs #Organoids #Regulatory #FDA #DrugDevelopment #DrugDiscovery

[iOrganBio @iOrganBio]

✍️ Design 🏗️ Build 💥 Test 💡 Learn

These are the core engineering principles that guide the iterative design of everything spanning ballpoint pens to fighter jets. And now we can do the same for cells—completely automated—made possible by advanced robotics and AI.

As part of Boston Tech Week, @iOrganBio Founder and CEO @DanielDelubac will be contributing to a panel discussing the intersection of deep tech and biomedical progress. Joining him for the Heeding Nature's Call: Reading the Body with AI are:

@JohnCapodilupo of @ThroneScience and @WHOOP
@LoyConor of @romixbio

Moderated by @drewvolpe of @FirstStarVC, this fireside chat promises to be an engaging update on how deep tech is combining with biotechnology to transform human health. If you’re in Boston for @Techweek_ , you won’t want to miss it!

📝 Register for the event at https://t.co/ICt9Q8tOUg
🤖 Check out the full Boston Tech Week lineup at https://t.co/JcAZQefnm0
🌐 Learn more about iOB at https://t.co/GkpfmsyGnf

#BOSTechWeek #AI #Biotech #Organoids #NAMs

[iOrganBio @iOrganBio]

iOrganBio is excited to share the addition of Jessica Owens to our Board of Directors. Bringing with her more than 20 years of experience in the venture capital world, Owens has a proven track record of building companies with impact across technology, life science, and healthcare sectors.

As @iOrganBio continues to build our technology platform, we’re grateful to have expertise and guidance from the world’s foremost scientists, engineers, and industry leaders. Together, we’re proud to be re-shaping how cell-based research and therapies are developed, expanding access to life changing therapeutics.

🚀 Welcome aboard Jessica!

📰 Read the full press release at https://t.co/FBwjs4kk0J
🌐 Learn more about iOB’s technology at https://t.co/FCJZoMdidY

[iOrganBio @iOrganBio]

We’re proud to congratulate @iOrganBio Co-Founder and Senior Scientific Advisor @ChenShuibing on her re-appointment to the @ISSCR Board of Directors.

As highlighted in the ISSCR’s announcement, this recognition reflects Dr. Chen’s continued leadership and influence in advancing stem cell research and regenerative medicine worldwide. Her work sits at the forefront of innovation—bridging fundamental science and translational impact.

We’re honored to have her guidance as part of our team and excited to see her ongoing contributions help shape the future of the field. Congratulations, Shuibing!

📄 Full link here https://t.co/DQQgepnlYw
🌐 Learn more about iOrganBio and our team at https://t.co/2erOow46Yo

[iOrganBio @iOrganBio]

🇨🇭The future of cell manufacturing is coming to the heart of Europe! Next week, iOB COO @karol_jarzabek will be heading to Basel, Switzerland for Swiss Biotech Day 2026.

As new approach methodologies gain traction, the need for efficient model development and scalable manufacturing continues to grow. Using the CellDiscovery™ platform’s parallel process development and CellForge™ cell and organoid manufacturing, @iOrganBio is providing our partners with The Right Cells, Consistently, At Scale.

There’s still time to register for Swiss Biotech Day, see the link below.

Event Details:
📆 May 4-5
📍 Basel, CH
🔗 https://t.co/y8aq97Uel4
@SwissBiotech
@SBC_Biopharma

#NAMs #Organoids #BioTech #Biopharma

[Drew Volpe @drewvolpe]

The FDA is replacing animal testing w/ human cell models. To do this, the field needs cell manufacturing that's precise, consistent, and scalable. @iOrganBio is how we'll get there.

[iOrganBio @iOrganBio]

✈️ Catch the iOrganBio team at these upcoming events around the globe!

The development of new approach methodologies (NAMs) hinges on the reliability and consistency of the cells that make them up. From organoids to microphysiological systems, adoption of NAMs, iOrganBio is helping partners accelerate process development with the CellDiscovery™ platform and bridge the gap between development and scalable production using CellForge™ manufacturing.

🌐 Find out more about our team and technology by visiting https://t.co/GkpfmsyGnf
✉️ To learn more about working with iOB email [email protected]

#ProcessDevelopment #Biomanufacturing #iPSCs #NAMs #Organoids

@WCM_Innovation
@ncbiotech
@NCLifeSci
@SwissBiotech
@SBC_Biopharma

[iOrganBio @iOrganBio]

💣 Early clinical development is fraught with risk for drug developers 💥

One of the best ways to mitigate risk of early failures in the clinic is by ensuring that the program’s preclinical data is built on a solid biological foundation, leveraging the latest technical advances from across the biotechnology ecosystem.

🎙️ In this episode of the @PharmTechGroup Drug Digest podcast, iOrganBio CEO @DanielDelubac explains how strategic partnering can both expand access to valuable tools and technologies for drug developers, as well as reduce the time-to-trial cost of advancing a drug development program.

@iOrganBio is proud to be a key player in this partnering ecosystem, accelerating drug discovery through our technology platform components:

🔬 Rapid parallelized in vitro model development with CellDiscovery™

🏭 Scalable and consistent cellular manufacturing with CellForge™

📊 High-resolution state readouts and digitization with CellTelemetry™

When drugmakers identify a need, iOB is there to provide a solid biological foundation to build their work upon, delivering The Right Cells, Consistently, At Scale.

🎧 Catch the full Drug Digest Episode at https://t.co/5r4QdK8QWJ
✉️ Learn more about how iOB’s best-in-class models by emailing [email protected]
🌐 Explore the iOB technology platform at https://t.co/2erOow46Yo

#DrugDevelopment #Organoids #Biopharma #Biomanufacturing

[iOrganBio @iOrganBio]

🇰🇷 Big news for regenerative medicine in South Korea!

The @KoreaDCA announced earlier this week the launch of its clinical-grade stem cell distribution center as part of the Cell-Based Artificial Blood Manufacturing and Demonstration Platform.

🏭 As governments around the world continue to invest more into the development of advanced therapies and stem cell-derived treatments, the need for high quality cell manufacturing continues to grow; we're ready to be a part of this growing field of advanced therapies.

@iOrganBio's technology platform is designed to lead the next generation of biomanufacturing, built around modern technology and reimagining the principles of cell manufacturing from the ground up using single cell transcriptomics and AI-driven differentiation.

🚀 We look forward to what the future holds for regenerative medicine in Korea and beyond as we build the infrastructure that will expand access to these life changing medicines!

📄 Read the full article at https://t.co/ADdWfouu0I
🌐 Learn more about iOB at https://t.co/GkpfmsyGnf

[Blackwood Healthcare Breakthroughs @BHBreakthroughs]

@ollieforsyth @iOrganBio is building scalable human cell manufacturing that will enable transplants to reverse the aging process.

[iOrganBio @iOrganBio]

As March wraps up, we’re looking back at our coast-to-coast travels and the many opportunities we had to share our vision for the future of biomanufacturing, drug discovery and development, and the advancement of impactful therapeutics. Pictured are just a few of the stops along the way, including:

🌱 @SOSV Investor Showcase & Demo Day

🤝 Hope is Not a Workflow: Turning Collaboration Into Clinical and Manufacturing Impact Symposium

🤖 @NCStateBTEC AI in Biomanufacturing Symposium

🚀 Center for Entrepreneurial Development Venture Connect NC

Thank you to all the organizers across the scientific and business worlds to make these events possible!

As we look forward to the future, we’re excited to be expanding our partnership network, building upon our technological success, and providing the protocols, infrastructure and capabilities to manufacture The Right Cells, Consistently, At Scale.

✉️ To partner with us, reach out to [email protected]
🌐 Learn more about our technology and team at https://t.co/GkpfmsyGnf

#Biomanufacturing #DrugDiscovery #Biotechnology #AI

[iOrganBio @iOrganBio]

🚛 Delivering impactful therapies to patients takes more than good science. It requires a fully integrated chain of highly interconnected processes spanning pre-clinical development to manufacturing to quality assurance to the clinic.

Join us for the Hope is Not a Workflow Symposium, a gathering focused on transforming collaboration into measurable manufacturing outcomes and clinical impact. Learn how aligned partnerships, shared standards, and practical execution can accelerate the path from discovery to scalable, commercial-ready therapies.

iOrganBio is proud to sponsor this event, bringing together leading figures in biopharma to solve problems and overcome challenges. We extend our thanks to founding partners @pluristyx and Teknova for putting on this event.

As an innovator in intelligent cell manufacturing, we’re redefining how human cells are engineered and reliably produced at scale for research and therapy. Together with our partners, we’re expanding access to life-changing therapies, developed with The Right Cells, Consistently, At Scale.

📋 Learn more and register for the event at https://t.co/RI5niffeHm
📆 Mar 25, 2026
⏰ 8:00am - 7:00pm
📍@ncbiotech

🌐 Learn more about iOB and our platform by visiting https://t.co/FCJZoMdidY

#DrugDevelopment #Biomanufacturing #AdvancedTherapies #Biopharma

[iOrganBio @iOrganBio]

Artificial intelligence continues to transform the landscape of drug discovery, and the progress is only accelerating. In this clip from the Pharm Tech Drug Digest Podcast, CEO @DanielDelubac discusses how AI is being leveraged across the entirety of the drug development pipeline, from the design of drugs themselves to in silico modeling.

New Approach Methodologies (NAMs) are a key part of this new wave of drug discovery. Using the CellDiscovery™ platform, iOrganBio is equipping partners with a powerful platform to discover, develop, and refine their cell and organoid models.

Whether testing cell therapy efficacy, generating safety data using non-animal models, or customizing models for n-of-one drug discovery, we are providing biopharma with The Right Cells, Consistently, At Scale.

🎧 Listen to the whole Drug Digest episode at https://t.co/hXBJluy6a8
🌐 Learn more about the iOB technology platform at https://t.co/2erOow46Yo

#AI #DrugDiscovery #DrugDevelopment #Biopharma #NAMs #Organoids

[iOrganBio @iOrganBio]

Coming up later this week, CEO @DanielDelubac joins pioneers across industry and academia at the 2026 Symposium on Applied AI in Biomanufacturing. Hosted by NC State BTEC, the conference will highlight key areas of innovation in the space including:

⚙️ Application of AI to improve manufacturing processes

📊 AI enhancement of analytical capabilities and release testing

🔎 Integration of AI in the quality oversight processes to improve decision-making

🚧 Challenges of AI integration, implementation and maintenance in a regulated environment

@iOrganBio is proud to be a part of North Carolina’s thriving biotechnology and biomanufacturing ecosystems. By leveraging our automated transcriptomics platform to digitize cell state, we are able to unlock the potential of AI to build better biological models and manufacture cells and organoids with precision, all with unprecedented reliability and scale.

💻 Learn more about the event and join at https://t.co/fv3lUeOhIO
📅 March 12, 2026
⏰ 8:00am to 6:00pm
📍 Hybrid (Raleigh or Virtual)

🌐 Learn more about iOrganBio and our technology at https://t.co/FCJZoMdidY

#AI #Biomanufacturing #Quality #ProcessDevelopment

[iOrganBio @iOrganBio]

We’re getting ready to take the stage for Demo Day at @indbio Investor Showcase. This exclusive investor event features early stage companies within the IndieBio portfolio working to advance human and planetary health.

@iOrganBio is proud to be a part of an impressive line-up of ventures and to have the opportunity to share about our technology platform that is revolutionizing cell manufacturing. By digitizing cell states and leveraging the latest advancements in AI and automation, we’re expanding access to new cell and organoid types, accelerating process development of biological models, and empowering our partners’ impactful work that brings new therapies from the bench into the clinic.

In the biopharma sector, the foundation of new therapies starts with cells, and at iOB we’re providing the means to manufacture The Right Cells, Consistently, At Scale.

Event Details:
📆 March 11 2026
🏙️ Onsite event 2:00pm to 5:00pm
💻 Virtual event 5:00pm
📍 New York, NY

📝 To be a part of the action, register at https://t.co/S4xTQStuAn
🌐 To learn more about iOrganBio and our tech, visit https://t.co/2erOow4ENW

#deeptech #organoids #stemcells #venturecapital

[Stem Cell Podcast @stemcellpodcast]

🎙️ We have a new episode out!

We chat with Drs. Shuibing Chen (@ChenShuibing) and Hans Clevers (@HansClevers) from the #ISSCR Consortium on Advanced Stem Cell-Based Models in Drug Discovery and Development

They discuss how stem cell–derived organoids and other new approach methodologies (#NAMs) can complement or replace animal models in preclinical research.

🔊 Listen now: https://t.co/pFpwozH6he

[iOrganBio @iOrganBio]

🎙️ iOB Co-Founder and Senior Scientific Advisor @ChenShuibing was recently featured on the @stemcellpodcast, the leading podcast dedicated to discussing the latest trends in stem cell research and innovation.

Joining organoid pioneer @HansClevers, Dr. Chen discussed the latest developments in new approach methodologies (NAMs) adoption, and the need for improved reproducibility and sound predictivity to drive the development of human-relevant therapies.

@iOrganBio is proud to be at the forefront of this revolution in biological modeling.

🔭 Using the CellDiscovery™ platform, we are accelerating process development and iteratively improving the bioequivalence, expanding access to new models and functional states, and increasing consistency and reliability of the next generation of cell and organoid models.

🎧 Listen to full episode at https://t.co/MLqAX9yHAz
🌐 Learn more about iOrganBio at https://t.co/GkpfmszecN

#iPSC #organoids #NAMs #StemCells